In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $50.00.
Tara Bancroft’s rating is based on several factors, including the recent updates to the TG Therapeutics model in line with the TD Cowen Biotech’s Q1:25 earnings preview. The analyst has slightly increased the net revenue estimate for Briumvi to $117 million, up from the previous estimate of $115 million, indicating a positive outlook on the company’s revenue potential. Additionally, the research and development expenses have been adjusted to $23 million from the prior $20 million, reflecting a strategic investment in future growth. Despite these changes, the earnings per share estimate for the quarter is slightly reduced to $0.18 from $0.19, which suggests a balanced view of the company’s financial health.
Tara Bancroft maintains a discounted cash flow-based price target of $50.00, reinforcing confidence in the stock’s long-term value. The Buy rating is supported by the belief in the company’s ability to achieve its financial targets and the potential for future growth, making TGTX an attractive investment opportunity.
In another report released on April 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.